

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant	:	Clackson et al.
USSN	:	
Filed	:	
For	:	Regulation of Biological Events Using Novel Compounds

November 18, 2003

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Preliminary Amendment**

**Please make the following amendments to the specification:**

***Please insert the following on page 1 of the application, after the Title and before "Background of the Invention":***

-- This application is a continuation of USSN 09/781,804 filed 2/12/01, which is a divisional application of USSN 09/012,097 filed 1/22/1998 (now US Patent 6,187,757) as a continuation in part of USSN 08/791,044 filed 1/28/97 (now abandoned), which itself is a continuation in part of USSN 08/481,941 filed 6/7/95, (now abandoned) and of U.S.S.N. 60/015,502 filed 2/9/96 and claimed the priority benefit of International Application No. PCT/US96/09948 filed internationally 6/7/96, the entire contents of each of these applications are hereby incorporated by reference. --

***Please amend page 14 to replace the paragraph on lines 10 - 13 with the following:***

~~Figure 2 depicts the results of transcription assays using rapalogs 42, 53, 69 and 96, synthesized as described herein, as dimerizer. Rapalog-s were tested in cells expressing wild type FRB (Figs. 2A and 2C) as well as in cells expressing a mutant FRB in which Thr 2098 was replaced by Leu (Figs 2B and 2D) or by Phe (Fig 2E).~~

Figure 2A depicts results of transcription assays using rapalog 96, synthesized as described herein, as the dimerizer. The rapalog was tested in cells expressing wild-type FRB. A rapamycin control is shown.